0001209191-23-035977.txt : 20230609 0001209191-23-035977.hdr.sgml : 20230609 20230609173449 ACCESSION NUMBER: 0001209191-23-035977 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230608 FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Greene John CENTRAL INDEX KEY: 0001610732 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 231006507 MAIL ADDRESS: STREET 1: 51 LIME STREET CITY: LONDON STATE: X0 ZIP: EC3M 7DQ ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-08 0 0001674416 CRISPR Therapeutics AG CRSP 0001610732 Greene John C/O CRISPR THERAPEUTICS, INC. 105 WEST FIRST STREET BOSTON MA 02127 1 0 0 0 0 Stock Option (Right to Buy) 62.59 2023-06-08 4 A 0 13000 0.00 A 2033-06-08 Common Shares 13000 13000 D This option was granted on June 8, 2023 with respect to 13,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2023; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2024 Annual General Meeting of Shareholders. /s/ Elizabeth Ryland Waldinger, attorney-in-fact 2023-06-09